Search
Encenicline
go.drugbank.com/drugs/DB11726InvestigationalEncenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.
Categories: Heterocyclic Compounds, 1-RingIcotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalVonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H<sup>+</sup>, K<sup>+</sup>-ATPase-mediated gastric acid secretion. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineEbastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: EVASTEL Z, PINAVALT® SOLUCIONTalazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein substratesTenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigationala novel alternative in the treatment of IBS-C. … Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRalimetinib
go.drugbank.com/drugs/DB11787InvestigationalRalimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others.
Categories: Heterocyclic Compounds, 1-RingTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalMarketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigationalChagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas. … [L15366] The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without symptoms.
Categories: Heterocyclic Compounds, 1-RingNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 奈拉替尼